Literature DB >> 18309031

HIF-1-dependent repression of adenosine kinase attenuates hypoxia-induced vascular leak.

Julio C Morote-Garcia1, Peter Rosenberger, Johannes Kuhlicke, Holger K Eltzschig.   

Abstract

Extracellular adenosine has been implicated in vascular adaptation to hypoxia. Based on the observation that increases in intracellular adenosine can effectively elevate extracellular adenosine, we studied the contribution of adenosine kinase (AK, intracellular conversion of adenosine to adenosine monophosphate [AMP]) to vascular adenosine responses. Initial in vitro studies of ambient hypoxia revealed prominent repression of endothelial AK transcript (85% +/- 2% reduction), protein, and function. Transcription factor binding assays and hypoxia inducible factor 1-alpha (HIF-1alpha) loss- and gain-of-function studies suggested a role for HIF-1alpha in transcriptional repression of AK. Moreover, repression of AK by ambient hypoxia was abolished in conditional HIF-1alpha mutant mice in vivo. Studies of endothelial barrier function revealed that inhibition or siRNA repression of AK is associated with enhanced adenosine-dependent barrier responses in vitro. Moreover, in vivo studies of vascular barrier function demonstrated that AK inhibition with 5'-iodotubericidin (1 mg/kg prior to hypoxia) significantly attenuated hypoxia-induced vascular leakage in multiple organs and reduced hypoxia-associated increases in lung water. Taken together, our data reveal a critical role of AK in modulating vascular adenosine responses and suggest pharmacologic inhibitors of AK in the treatment of conditions associated with hypoxia-induced vascular leakage (eg, sepsis or acute lung injury).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18309031     DOI: 10.1182/blood-2007-11-126763

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  104 in total

Review 1.  Hypoxic tumor microenvironment: Implications for cancer therapy.

Authors:  Sukanya Roy; Subhashree Kumaravel; Ankith Sharma; Camille L Duran; Kayla J Bayless; Sanjukta Chakraborty
Journal:  Exp Biol Med (Maywood)       Date:  2020-06-27

2.  Toll-like receptor signaling during myocardial ischemia.

Authors:  Tobias Eckle; Holger K Eltzschig
Journal:  Anesthesiology       Date:  2011-03       Impact factor: 7.892

Review 3.  Adenosine and hypoxia-inducible factor signaling in intestinal injury and recovery.

Authors:  Sean P Colgan; Holger K Eltzschig
Journal:  Annu Rev Physiol       Date:  2011-11-19       Impact factor: 19.318

4.  Signaling through the A2B adenosine receptor dampens endotoxin-induced acute lung injury.

Authors:  Ulrich Schingnitz; Katherine Hartmann; Christopher F Macmanus; Tobias Eckle; Stephanie Zug; Sean P Colgan; Holger K Eltzschig
Journal:  J Immunol       Date:  2010-03-26       Impact factor: 5.422

Review 5.  Extracellular adenosine: a safety signal that dampens hypoxia-induced inflammation during ischemia.

Authors:  Almut Grenz; Dirk Homann; Holger K Eltzschig
Journal:  Antioxid Redox Signal       Date:  2011-04-11       Impact factor: 8.401

Review 6.  Interactions between nitric oxide and hypoxia-inducible factor signaling pathways in inflammatory disease.

Authors:  Nels Olson; Albert van der Vliet
Journal:  Nitric Oxide       Date:  2011-01-01       Impact factor: 4.427

Review 7.  Ischemia and reperfusion--from mechanism to translation.

Authors:  Holger K Eltzschig; Tobias Eckle
Journal:  Nat Med       Date:  2011-11-07       Impact factor: 53.440

8.  Adenosine kinase inhibition enhances microvascular dilator function and improves left ventricle diastolic dysfunction.

Authors:  Alec Davila; Yanna Tian; Istvan Czikora; Amanda S Weissman; Nicholas Weinand; Guangkuo Dong; Jiean Xu; Jie Li; Huabo Su; Gaston Kapuku; Yuqing Huo; Zsolt Bagi
Journal:  Microcirculation       Date:  2020-05-25       Impact factor: 2.628

9.  Central role of Sp1-regulated CD39 in hypoxia/ischemia protection.

Authors:  Holger K Eltzschig; David Köhler; Tobias Eckle; Tianqing Kong; Simon C Robson; Sean P Colgan
Journal:  Blood       Date:  2008-09-23       Impact factor: 22.113

Review 10.  Adenosine receptors as drug targets--what are the challenges?

Authors:  Jiang-Fan Chen; Holger K Eltzschig; Bertil B Fredholm
Journal:  Nat Rev Drug Discov       Date:  2013-04       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.